Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases.

Their research and development is focused on disease targets as Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV). The company is listed on the NASDAQ.

Company: Enanta
Fund: alpinvest
Status: Realized
Team member: Harrold van Barlingen
Technology: Therapeutics
Website: www.enanta.com